<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Migraine Headaches and Migraine Headache Drugs</title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
    <md:title>Introduction to Migraine Headaches and Migraine Headache Drugs</md:title>
    <md:content-id>m00264</md:content-id>
    <md:uuid>adb46e47-e013-4a89-bf0e-00e3a3ab6218</md:uuid>
  </metadata>
<content>
<section class="learning-objectives" id="sect-00001">
<title>Learning Outcomes</title>
<para id="para-00001">By the end of this section, you should be able to:</para>
<list id="list-00001">
<item>Describe the pathophysiology of migraine headaches.</item>
<item>Identify the clinical manifestations related to migraine headaches.</item>
<item>Identify the etiology and diagnostic studies related to migraine headaches.</item>
<item>Identify the characteristics of drugs used to treat migraine headaches.</item>
<item>Explain the indications, action, adverse reactions, and interactions of drugs used to treat migraine headaches.</item>
<item>Describe nursing implications of drugs used to treat migraine headaches.</item>
<item>Explain the client education related to drug used to treat migraine headaches.</item>
</list>
</section>
<para id="para-00002"><term id="term-00001">Headaches</term> are a prevalent medical condition that can cause pain or discomfort in the head or neck area. Among the different types of headaches, <term id="term-00002">migraine headaches</term> are a specific and recurring type of headache that can cause significant debilitating symptoms. This chapter will focus specifically on migraine headaches, exploring their causes, symptoms, and common drugs used to alleviate this condition.</para>
<section id="sect-00003">
<title>Overview of Migraine Headaches</title>
<para id="para-00003">Migraine headaches are a type of headache that can be recurring and are often associated with a range of symptoms that can greatly affect a person’s quality of life. These symptoms will be explored in more detail later in this chapter. Migraine headaches can last for several hours up to several days and can be debilitating, often interfering with daily activities. Some people may experience a warning symptom, known as an <term id="term-00003">aura</term>, which can include visual disturbances such as flashing lights or blind spots. Migraine headaches are a prevalent condition that affects a significant portion of the U.S. population, with an estimated 39 million people experiencing this type of headache (American Migraine Foundation, 2023).</para>
<section id="sect-00004">
<title>Etiology</title>
<para id="para-00004">Migraines can stem from a range of factors, which may include environmental, potent odors, tobacco use, motion sickness, hormonal fluctuations, flashing lights, inadequate sleep, heightened stress levels, and certain foods such as aged cheeses, aspartame, and monosodium glutamate (MSG), and caffeine withdrawal (American Migraine Foundation, 2023; NIH, 2023).</para>
</section>
<section id="sect-00005">
<title>Pathophysiology</title>
<para id="para-00005">The underlying pathophysiology of migraine headaches is unclear, but a comprehensive theory proposes the involvement of neuronal hyperexcitability, vasodilation of blood vessels—which triggers pain receptors—and inflammation in the brain (American Migraine Foundation, 2023).</para>
</section>
<section id="sect-00006">
<title>Diagnostic Testing</title>
<para id="para-00006">To diagnose migraine headaches, health care providers rely on the client’s report of symptoms, a detailed medical history, and a physical examination. Radiologic imaging, such as an MRI or CT scan may also be performed to rule out other potential causes of the headaches, such as brain tumors, meningitis, or ischemia (American Migraine Foundation, 2023).</para>
</section>
<section id="sect-00007">
<title>Clinical Manifestations</title>
<para id="para-00007">Clinical manifestations (symptoms) of migraine headaches include the following:</para>
<list list-type="bulleted" id="list-00002">
<item>Pulsating throbbing head pain</item>
<item>Muscle weakness</item>
<item>Language disturbances</item>
<item>Pupillary changes</item>
<item>Visual disturbances</item>
<item>Mood changes</item>
<item>Fluid retention</item>
<item>Increased urinary output</item>
</list>
<note class="link-to-learning" id="note-00001">
<media alt="atoms_isotopes">
<iframe width="560" height="315" src="https://openstax.org/r/migraine"/>
</media>
<para id="para-00008">Nucleus Medical Media presents an educational video on migraine headaches.</para>
</note>
</section>
</section>
<section id="sect-00008">
<title>Drugs Used to Treat Migraine Headaches</title>
<para id="para-00009">Migraine headaches can be treated through two distinct courses of therapy: abortive and preventive. <term id="term-00004">Abortive therapy</term> aims to relieve the symptoms of a migraine headache through drug administration. On the other hand, <term id="term-00005">preventive therapy</term> involves the use of drugs to prevent the occurrence of migraine headaches altogether.</para>
<section id="sect-00009">
<title>Triptans</title>
<para id="para-00010">Triptans are <term id="term-00006">serotonin agonists</term> that target the pathophysiological mechanism of migraine headaches, effectively eliminating symptoms. By selectively binding to serotonin receptors 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub>, triptans induce vasoconstriction of cranial arteries that are typically dilated during migraines. The vasoconstriction helps to reduce the intensity and duration of migraine headaches.</para>
<para id="para-00011"><link target-id="table-00001" document="m00264"/> lists common <term class="no-emphasis" id="term-00007">triptans</term> and typical routes and dosing for adult clients.</para>
<table class="vertically-tight" id="table-00001">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<thead>
<row>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Drug</span></emphasis></entry>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Routes and Dosage Ranges</span></emphasis></entry>
</row>
</thead>
<tbody>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00008">Eletriptan</term><newline/>
(<term class="no-emphasis" id="term-00009">Relpax</term>)
</entry>
<entry valign="top" align="left">Single doses of 20 mg to 40 mg oral once<newline count="2"/>
If the migraine has not resolved by 2 hours after taking eletriptan, or returns after transient improvement, a second dose may be administered at least 2 hours after the first dose<newline count="2"/>
The maximum daily dose should not exceed 80 mg</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00010">Rizatriptan</term><newline/>
(<term class="no-emphasis" id="term-00011">Maxalt</term>)</entry>
<entry valign="top" align="left">The recommended starting dose is either 5 mg or 10 mg oral once, for acute treatment of migraines in adults<newline count="2"/>
May repeat dose after at least 2 hours if headache returns<newline/>
Maximum daily dose should not exceed 30 mg</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00012">Zolmitriptan</term><newline/>
(<term class="no-emphasis" id="term-00013">Zomig</term>)</entry>
<entry valign="top" align="left">The recommended starting dose is 1.25 mg or 2.5 mg<newline/>
The maximum recommended single dose of zolmitriptan is 5mg<newline count="2"/>
If the migraine has not resolved by 2 hours after taking zolmitriptan or returns after a transient improvement, a second dose may be administered at least 2 hours after the first dose<newline/>
Maximum daily dose is 10 mg in a 24-hour period</entry>
</row>
</tbody>
</tgroup>
<caption>Drug Emphasis Table: <term class="no-emphasis" id="term-00014">Triptans</term> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
</section>
<section id="sect-00010">
<title>Adverse Effects and Contraindications</title>
<para id="para-00012">Adverse effects of triptans include dizziness, nausea, flushing, tingling, neck pain, chest tightness, and paresthesia. Triptans are contraindicated in clients with a history of myocardial infarction, coronary artery disease, stroke, uncontrolled hypertension, and peripheral vascular disease (Nicholas &amp; Nicholas, 2023).</para>
<note class="black-box" id="note-00002">
<para id="para-00013"><emphasis effect="bold">Sumatriptan</emphasis></para>
<para id="para-00014">There is cardiovascular risk from sumatriptan with an increased risk of adverse thrombotic events, including myocardial infarction and stroke.</para>
</note>
<para id="para-00015">The drug prototype for triptans is <term class="no-emphasis" id="term-00015">sumatriptan</term> (<term class="no-emphasis" id="term-00016">Imitrex</term>). <link target-id="table-00002" document="m00264"/> is a drug prototype table for triptans featuring sumatriptan. It lists drug class, mechanism of action, adult dosages, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00002">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Serotonin agonists<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Selectively binds to serotonin receptors 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> and induces vasoconstriction of cranial arteries
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
The recommended daily doses are 25 mg, 50 mg, or 100 mg orally<newline count="2"/>
If the migraine has not resolved by 2 hours after taking sumatriptan or returns after a transient improvement, a second dose may be administered at least 2 hours after the first dose<newline count="2"/>
Maximum daily dose is 200 mg in 24 hours<newline count="2"/>
Subcutaneous dosing 6 mg with a maximum dose of 12 mg/day. Maximum dosing should be 2–6 mg injections separated at least 1 hour apart<newline count="2"/>
Intranasal doses are 5 mg, 10mg, and 20 mg given as a single spray in one nostril<newline count="2"/>
The maximum daily dose is 40 mg in a 24-hour period</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat migraine headaches<newline/>
To treat cluster headaches<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces migraine and cluster headaches</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Ergot containing drugs<newline/>
Monoamine oxidase inhibitors<newline/>
Selective serotonin reuptake inhibitors<newline/>
Serotonin and norepinephrine reuptake inhibitors<newline/>
Tricyclic antidepressants<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions
</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Paresthesia<newline/>
Flushing<newline/>
Vertigo<newline/>
Malaise<newline/>
Hypotension<newline/>
Dystonia
</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
Ischemic coronary disease<newline/>
Stroke<newline/>
Peripheral vascular disease<newline/>
Uncontrolled hypertension<newline/>
Pregnancy<newline count="2"/>
Caution:<newline/>
Monitor closely for arrhythmias including ventricular tachycardia and ventricular fibrillation, which can lead to death
</entry>
</row>
</tbody>
</tgroup>
<caption>Drug Prototype Table: Sumatriptan (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<section id="sect-00011">
<title>Ergot Alkaloids</title>
<para id="para-00016"><term class="no-emphasis" id="term-00017">Ergot alkaloids</term> are <term id="term-00018">alpha-adrenergic blockers</term>, a class of drug that directly stimulates vascular smooth muscle, thereby causing vasoconstriction. These alpha-adrenergic blockers are used in the treatment of migraine and vascular headaches, as well as other medical conditions such as hypertension. Adverse effects include coronary and peripheral ischemia, muscle pains, nausea, vomiting, paresthesias, vertigo, weakness, and itching. Ergot alkaloids are contraindicated in hypersensitivity to the drug or any of its components, peripheral vascular disease, coronary heart disease, hypertension, impaired hepatic or renal function, and sepsis.</para>
<note class="black-box" id="note-00003">
<para id="para-00017"><emphasis effect="bold">Ergotamine</emphasis></para>
<para id="para-00018">Ergotamine is contraindicated with potent inhibitors CYP3A4 drugs. Concomitant use of these drugs may result in serious vasospasm producing cerebral limb ischemia.</para>
</note>
<para id="para-00019">The most common ergot alkaloid used in the treatment of migraine headaches is ergotamine <term class="no-emphasis" id="term-00019">tartrate</term> (<term class="no-emphasis" id="term-00020">Cafergot</term>). <link target-id="table-00003" document="m00264"/> is a drug prototype table for ergot alkaloids featuring ergotamine tartrate. It lists drug class, mechanism of action, adult and pediatric dosages, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00003">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Ergot alkaloid and alpha-adrenergic blocker<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Inhibits norepinephrine and directly stimulates vascular smooth muscle, causing vasoconstriction</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
<emphasis effect="italics">Starting dose:</emphasis> 1 mg to 2 mg sublingually at the first sign on a migraine and 1 mg additional sublingually every ½ hour, if needed for full relief.<newline count="2"/>
<emphasis effect="italics">Maximum dose</emphasis>: 6 mg in 24 hours<newline count="2"/>
Also available in suppository form and in tablets with caffeine</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat migraine and vascular headaches<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces headache symptoms</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Ritonavir<newline/>
Indinavir<newline/>
Erythromycin<newline/>
Clarithromycin<newline/>
Troleandomycin<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Paresthesia<newline/>
Nausea<newline/>
Vomiting<newline/>
Weakness<newline/>
Vertigo<newline/>
Transient tachycardia or bradycardia<newline/>
Hypertension</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline/>
Vasoconstrictive conditions such as peripheral vascular disease and coronary heart disease<newline/>
Renal insufficiency<newline/>
Hepatic insufficiency<newline/>
Myocardial ischemia/infarction<newline count="2"/>
Caution:<newline/>
Monitor closely in clients who have bronchial asthma</entry>
</row>
</tbody>
</tgroup>
<caption>Drug Prototype: Ergotamine Tartrate (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00012">
<title>Selective Serotonin Receptor Agonists</title>
<para id="para-00020">Selective serotonin receptor agonists are a novel drug class that is used in the treatment of migraine headaches. It is centrally and peripherally acting 5-HT1F receptor agonist that decreases the release of neuropeptides and the neurotransmitter glutamate, thereby inhibiting neuronal firing. Adverse effects include paresthesia, fatigue, drowsiness, nausea, vomiting, muscle weakness, and hypertension. They are contraindicated in hypersensitivity to the drug or its components (Berger et al., 2020).</para>
<para id="para-00021">The most prescribed selective serotonin receptor agonist for migraine headaches is <term class="no-emphasis" id="term-00021">lasmiditan</term> (<term class="no-emphasis" id="term-00022">Reyvow</term>), <link target-id="table-00004" document="m00264"/> is a drug prototype table for <term class="no-emphasis" id="term-00023">selective serotonin receptor agonists</term> featuring lasmiditan. It lists drug class, mechanism of action, adult dosages, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00004">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
Selective serotonin receptor agonist<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Decreases the release of neuropeptides and the neurotransmitter glutamate, inhibiting neuronal firing</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Recommended dose is 50 mg, 100 mg, or 200 mg taken orally, as needed<newline count="2"/>
No more than one dose should be taken in 24 hours</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat migraine and cluster headaches<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces migraine and cluster headache symptoms</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Selective serotonin reuptake inhibitors<newline/>
Serotonin and norepinephrine reuptake inhibitors<newline/>
Tricyclic antidepressants<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Paresthesia<newline/>
Drowsiness/sedation<newline/>
Nausea and vomiting<newline/>
Muscle weakness<newline/>
Fatigue<newline/>
Serotonin Syndrome</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline count="2"/>
Caution:<newline/>
Monitor closely in clients who are taking other drugs associated with serotonin syndrome as coadministration of lasmiditan with these drugs can cause serotonin syndrome<newline/>
Monitor closely for central nervous system depression/impaired driving</entry>
</row>
</tbody>
</tgroup>
<caption>Drug Prototype: Lasmiditan (Reyvow) (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
<section id="sect-00013">
<title>Calcitonin Gene Related Peptide (CGRP) Receptor Antagonists</title>
<para id="para-00022"><term class="no-emphasis" id="term-00024">Calcitonin gene related peptide (CGRP) receptor antagonists</term> are a novel drug class used in the treatment of migraine headaches. They block CGRP receptors and inhibits the biological activity of CGRP neuropeptides. Adverse effects include nausea, rash, and dyspnea. Contraindications include hypersensitivity to the drug or its constituents (Rashid &amp; Manghi, 2022).</para>
<para id="para-00023">The most prescribed CGRP receptor antagonist is <term class="no-emphasis" id="term-00025">rimegepant</term> (<term class="no-emphasis" id="term-00026">Nurtec</term>). <link target-id="table-00005" document="m00264"/> is a drug prototype table for CGRPs featuring rimegepant. It lists drug class, mechanism of action, adult dosages, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00005">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
CGRP receptor antagonist<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Binds to CGRP receptors, decreasing inflammation in the meninges of the brain</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
Recommended dose is 75 mg orally as needed<newline count="2"/>
<emphasis effect="italics">Maximum dose:</emphasis> 75 mg in a 24-hour period</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
To treat migraine headaches<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces migraine headaches</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Ritonavir<newline/>
Indinavir<newline/>
Amiodarone<newline/>
Cyclosporine<newline/>
Quinidine<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Nausea<newline/>
Rash<newline/>
Shortness of breath</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity<newline count="2"/>
Caution:<newline/>
Monitor closely in clients with hepatic insufficiency</entry>
</row>
</tbody>
</tgroup>
<caption>Drug Prototype: Rimegepant (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
</section>
<section id="sect-00014">
<title>Nursing Implications</title>
<para id="para-00024">The nurse should do the following when administering migraine headache drugs to clients:</para>
<list list-type="bulleted" id="list-00003">
<item>Assess the client’s medical history, current drug list, and allergies.</item>
<item>Assess client’s baseline symptoms, vital signs, and pain level.</item>
<item>Ensure the drug is prepared appropriately using aseptic technique and verify dosage before administration.</item>
<item>Monitor the client’s response to the drug, including any changes in pain level, neurological status, and vital signs.</item>
<item>Maintain a dark, calm, and quiet environment.</item>
<item>Educate the client about the drug, including its purpose, how to administer it, potential side effects, and when to call the health care provider. See below for additional client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00004">
<para id="para-00025"><emphasis effect="bold">The client taking a migraine headache drug should:</emphasis></para>
<list list-type="bulleted" id="list-00004">
<item>Get adequate sleep and rest.</item>
<item>Keep a journal of symptoms, the presence or non-presence of an aura, and improved or worsening symptoms.</item>
<item>Take migraine drugs as prescribed.</item>
<item>Identify food triggers, environmental triggers, hormonal triggers, and stress triggers.</item>
<item>Report worsening of symptoms such as visual changes and uncontrolled head pain to the health care provider immediately because these manifestations can be debilitating.</item>
</list>
<para id="para-00026"><emphasis effect="bold">The client taking a migraine headache drug <emphasis effect="italics">should not</emphasis>:</emphasis></para>
<list list-type="bulleted" id="list-00005">
<item>Drink alcohol or smoke as these can precipitate symptoms of migraine headaches.</item>
<item>Operate heavy equipment or machinery while taking migraine headache drugs.</item>
</list>
</note>
</section>
</content>
<glossary>
<definition id="def-00001"><term>abortive therapy</term> <meaning>therapy that aims to relieve symptoms through drug administration</meaning></definition>
<definition id="def-00002"><term>alpha-adrenergic blockers</term> <meaning>a class of drugs that bind and inhibit alpha-adrenergic receptors, thereby inhibiting smooth muscle contraction</meaning></definition>
<definition id="def-00003"><term>aura</term> <meaning>terminology used to describe the warning signs of an impending seizure</meaning></definition>
<definition id="def-00004"><term>headaches</term> <meaning>a prevalent medical condition that can cause pain or discomfort in the head or neck area</meaning></definition>
<definition id="def-00005"><term>migraine headaches</term> <meaning>a type of headache that can be recurring and are often associated with a range of symptoms that can greatly affect a person’s quality of life</meaning></definition>
<definition id="def-00006"><term>preventive therapy</term> <meaning>the use of drugs to prevent the occurrence of a condition</meaning></definition>
<definition id="def-00007"><term>serotonin agonists</term> <meaning>drugs that bind to and activate serotonin receptors, often used in the treatment of depression, anxiety, and migraine headaches</meaning></definition>
</glossary>
</document>